TYRA as reported
- Net Income
- −$149M
Net Income · +40% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$110M
Free Cash Flow · +27% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.39
EPS · +34% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$149M | +40% | Q2 2026 |
| EPS | −$2.39 | +34% | Q2 2026 |
| ROE | −40% | n/a | Q2 2026 |
| ROA | −38% | n/a | Q2 2026 |
| Free Cash Flow | −$110M | +27% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Tyra Biosciences, Inc. (TYRA) - Net IncomeNet IncomeTyra Biosciences, Inc. (TYRA)